Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution